Generics are the winners as CAFC doubles down on strict Hatch-Waxman venue selection criteria

A decision handed down last Friday against Celgene elaborates on the rules set out in the landmark Valeant case and makes life tough for pharma patent owners

Get unlimited access to all IAM content